Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Inclusion Criteria: * Histologically proven and reviewed well differentiated malignant pancreatic sporadic NET Metastatic disease not amenable to surgical resection * All target lesions (lesions measurable and non-measurable according to the RECIST 1.1 criteria), of a size ≥ 15 mm, twice the spatial resolution of the somatostatin receptor scintigraphy (SRS), should be positive (grade of uptake at SRS≥ 2, equal to the physiologic liver uptake) within 24 weeks prior to enrollment. Negative target lesions are acceptable if below 15mm. * Post first line whatever the type of systemic therapy: cytotoxic chemotherapy or everolimus or somatostatine analogs… Only one line of cytotoxic chemotherapy is authorized. * Evaluable disease according to RECIST 1.1 criteria (Appendix 2) * Progressing disease within 12 months prior to randomization according to RECIST 1.1 criteria ; * ECOG performance status 0-2 (appendix 9) * Life expectancy ≥ 6 months as prognosticated by the physician * Age ≥ 18 years, no superior limit * Adequate bone marrow reserve (Hb \> 8, neutrophils ≥ 1500/mm³ and platelets ≥80.000/mm\^3) * Effective contraception in pre-menopausal female and male patients during and for at least 6 months post-treatment. * Patient´s signed written informed consent * Ability to comply with the protocol procedures * Ability to take oral medication * Patient affiliated to a social security system or beneficiary of the same. Exclusion Criteria: * Large or small cell-poorly differentiated…